Introduction
The incidence of HIV-1 infection is increasing among women in Taiwan and worldwide. Most infections occur through heterosexual transmission [1] . Emerging data show that some aspects of HIV disease may differ between men and women [2, 3] . A knowledge of sex-specific differences may elucidate important determinants of risk of heterosexual and perinatal transmission, increase our understanding of HIV-1 pathogenesis, help in the analysis of therapeutic effects and design of prevention strategies, and enhance our understanding of the factors that influence disease progression in women, including the potential role of sex hormones.
Recent studies found that, for a given CD4 cell count, women had plasma HIV-1 RNA levels approximately 30-50% lower than those in men [3] . Several lines of evidence suggest that hormonal variations through the menstrual cycle could have an impact on viral dynamics in the female genital tract. However, two recent publications have reported contradictory results about the effect of sex hormones on HIV-1 virus burden [4, 5] . Although the biological basis for sexrelated differences in HIV infection is most likely to be hormonal, little is known about the effects of endogenous and exogenous sex hormones on the course of HIV infection. Few studies have attempted to address the issue of potential variation of peripheral blood and genital tract viral load through the menstrual cycle [6] [7] [8] . It is unclear whether hormonal changes during the menstrual cycle affect immunologic markers in HIVinfected women. The objectives of this study were to determine whether the lymphocyte subsets and their immunologic markers change during the follicular and luteal phases and to further discuss the effect of sex hormones on the disease course of HIV-seropositive women.
Methods

Participants
Between October 1997 and 2001, the study enrolled 21 HIV-infected women, all of whom had enzyme-linked immunosorbent assay and Western immunoblotting evidence of HIV infection, and 30 matched controls. All subjects were over 18 years of age, not pregnant, and had regular menstrual cycles (25-30-day interval, variation smaller than 3 days) during the preceding 6 months. Women were excluded if they had received a vaccination, narcotics, estrogens, progestins, or antiretroviral medications. Participants were recruited at National Taiwan University Hospital and followed during a routine, monthly visit by the same investigator (HNH). At least six blood samples were collected from each patient.
Study design
Historical and physical data were obtained by trained interviewers and research clinicians. Participants were asked to contact project staff within 3 days of the onset of menstrual bleeding and were then scheduled for studies in the menstrual period, follicular and luteal phases. Weight, height, body mass index, medications, menstrual history, smoking status, and confirmation of the presence of serum HIV antibody were recorded. Medical history was updated (dates of onset of menstruation, new medications, use of illicit drugs, and acute illnesses). A detailed pelvic examination, at which cervical and vaginal secretions and exfoliated cells were collected for another study, and phlebotomy were performed at each visit.
Laboratory methods
Because serial ovarian ultrasonography and daily serum sampling were not performed, menstrual phase was determined by careful review of menstrual history and endocrine analyses of blood samples. Peripheral blood was collected between 7:30 and 9:30 AM by venipuncture into glass collection tubes. Serum was separated and frozen for batch testing. Serum concentrations of follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone were quantified in duplicate using the IMMULITE immunoassay system (Diagnostic Products Corporation, Los Angeles, CA, USA) with inter-and intra-assay coefficients of variation of less than 11% and less than 8%, respectively. Peripheral blood mononuclear cells (PBMCs) were separated by Ficoll-Paque gradient centrifugation and resuspended in a solution containing 90% RPMI -1640 and 10% heat-inactivated fetal calf serum (FCS).
T 
No difference in percentages of lymphocyte subsets in both phases
There was no difference in the percentage of various lymphocyte subsets between HIV-positive and normal women in either the follicular or luteal phase (Table 2 ). CD8 + cell counts were increased in the luteal phase compared with the follicular phase in normal women. However, this increase disappeared in HIV-positive women. HIV infection led to an increase in CD8 + cells during the follicular phase of the menstrual cycle.
Increased activation (HLA-DR and CD38) of CD8 + T cells in HIV-positive women
An increase in expression of the activation markers HLA-DR and CD38 was seen exclusively on CD8 + cells of HIV-positive women compared with controls (Table 3) . There were no changes in CD25 and CD69 expression on either CD4 + or CD8 + cells.
Discussion
AIDS was first reported in the USA in 1981 [9] , and its association with HIV infection was shown in 1983 [10] . In Taiwan, HIV infection is still rare. There were 6,552 cases reported by the Center for Disease Control up to November 2004, of which only 444 cases were female. Early studies suggested that HIV-infected women may progress to AIDS and death faster than men [12] . However, some studies have reported similar rates of CD4 + cell decline and time to AIDS between men and women [13] , and there is no gender difference in HIV-1 RNA levels [4, 5] . Nevertheless, these reports may have been limited by small sample size and by a failure to match fully for CD4 + cell counts. Recent data have suggested that HIV-1 RNA viral load measures are 38-65% lower in women than in men with a similar CD4 + count, which implies that at the same viral load, women have a higher risk of AIDS [3] . Anastos et al found that CD4 + cell decline was more rapid in women [14] . This more rapid decline suggests that clinical disease progression may be more rapid in women [3] . Many investigators have proposed that the different hormonal status of women and men has an effect on viral dynamics. Studies of HIV-uninfected persons indicate that women have significantly higher CD4 + cell percentages and counts than men [15] . Reproductive hormones are known to have effects on lymphocyte function and cytokine production [16] . Tumor necrosis factor-, which is associated with immune activation and increased viral replication, may be inhibited by estrogen, resulting in lower viral load [17] . Thus, based on the currently available data, there is a sex difference in the natural course of HIV disease, and the guidelines for the use of antiretroviral therapy in HIV-1 infection may be revised for women.
There are very few data on the effects of sex steroids on the progression of HIV infection, and no firm conclusions can be drawn. A simian model demonstrated an increase in plasma viral RNA levels after progesterone was implanted in seropositive macaques [18] . However, a study of HIV-infected women over 40 years of age demonstrated that the use of hormone replacement therapy was associated with an improved survival rate [19] . Nevertheless, when controlling for CD4 + cell count, use of antiretroviral therapy, and a history of AIDSdefining illnesses, hormonal contraceptive use was not associated with viral load changes over time, regardless of the type of oral contraceptive used [20] . Furthermore, several large studies of HIV infection in pregnancy have suggested no influence of gestation on disease progression [21, 22] . Therefore, the use of hormonal contraception and the hormonal changes during pregnancy seem to have no effect on the course of HIV-1 disease.
Studies have shown that the length of the menstrual cycle and the duration of menstrual bleeding are not significantly different between HIV-infected and -uninfected women, which suggests that most HIVinfected women ovulate monthly and have an intact hypothalamic-pituitary-ovarian axis [23] . Recent studies have shown that the amount of HIV-1 RNA in vaginal secretions is strongly correlated with that in plasma [24] . Several studies have examined mucosal virus levels at different times during the menstrual cycle in order to evaluate the influence of endogenous hormones on virus shedding [6] [7] [8] . These studies have generated variable results with evidence both for and against an impact of endogenous hormones on genital levels of virus. However, most studies demonstrated that plasma HIV-1 RNA levels did not change significantly from week to week during the menstrual cycle [6, 8] . This suggests that plasma estradiol and progesterone levels are not correlated with plasma virus load. Therefore, our results provide further evidence that hormonal changes during the menstrual cycle do not affect the immune cells in blood. Nevertheless, HIV infection changes the T-cell subsets and makes the differences across menstrual phases disappear.
Although the cytopathic effects of HIV on T cells in vitro have been well described, the "direct killing" hypothesis cannot account for all the complexities of the disease and indirect effects of HIV infection, primarily the wide and chronic immune activation of the host that it causes, and may better account for the main changes observed during HIV progression and AIDS [25] . Therefore, assessment of immune activation during followup of patients, especially after antiretroviral therapy, might be a more meaningful outcome measure of treatment success than measurement of viral load and CD4 + cell counts alone [26] . HIV-1 infection causes activation of B and T cells, which consequently upregulates the surface expression of CD38 and other activation markers, such as HLA-DR, as shown in our previous study [27] and this study. CD38 expression in CD8 + cells is upregulated at seroconversion and is maintained at high levels in those who are short progressors or decreases in subjects with stable CD4 + cell counts [28] . Because high proportions of CD8 + CD38 + T cells predict progression in HIV-1-infected adults, the high CD38 expression on CD8 + T cells is a marker of poor prognosis. In our patients, lymphocyte activation with increased CD38 expression is detrimental since this activation favors cell infection by upregulating molecules involved in HIV-1 replication [29] . However, the expression of early activation markers, CD69 and CD25, was not significantly changed on T cells from seropositive patients. The rapid expression of these activation antigens after mitogenic stimulation was used to evaluate the proliferative functionality of lymphocytes [30] . Because HIV infection itself impairs the propagation of T lymphocytes, the expression of CD69 and CD25 was not increased in these patients.
In the present study, we found that hormonal changes during the menstrual cycle did not have a significant effect on the distribution of systemic immune cells. The controversy about the potential role of sex hormones on the genital tract viral load may be due to local nonmenstrual factors, such as fluctuations in cytokine and chemokine concentrations and cytotoxic T-cell activity in the genital tract. Additional research is needed to identify these influencing factors and apply the knowledge to prevent the transmission of HIV-1 infection.
